HDAC2 has been implicated in the malignant phenotype of hepatocellular carcinoma via LAPTM4B activation and in cisplatin resistance in triple-negative breast cancer by modulating m6A-mediated DNA damage repair [56, 57]. Here, HDAC2 is linked to triple-negative breast carcinoma.